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Abstract 
Background: In Italy HPV vaccination with the quadrivalent vaccine  (Gardasil®) is offered actively and free of charge 
to girls aged 12 since 2007. A nine-valent vaccine (Gardasil  9®) received the European market authorization in 2015 
to protect, with only 2 doses, against around 90% of all HPV positive cancers, over 80% of high-grade precancerous 
lesions and 90% of genital warts caused by HPV types 6/11.
Methods: A dynamic transmission model simulating the natural history of HPV-infections was calibrated to the Ital-
ian setting and used to estimate costs and QALYs associated with vaccination strategies. The analyses compared two 
strategies with the nine-valent vaccine (cervical cancer screening and vaccination in girls only or vaccination in boys 
and girls) to four alternative strategies (cervical cancer screening and vaccination with quadrialent vaccine in girls 
only, in both boys and girls, with bivalent vaccine in girls and screening strategy only). The National Health Service 
perspective was considered.
Conclusion: The switch to the nine-valent vaccine in Italy can further reduce the burden associated to cervical can-
cer and HPV-related diseases and is highly cost-effective.
Results: Compared to the current vaccination program with quadrivalent vaccine, the nine-valent vaccine in a 
programme including girls and boys shows further reductions of 17% in the incidence of cervical cancer, 35 and 14% 
in anal cancer for males and females, as well as over a million cases of genital warts avoided after 100 years. The new 
technology is associated with an ICER of 10,463€ per QALY gained in universal vaccination, decreasing to 4483€ when 
considering the vaccine switch for girls-only.
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Background
Human papillomavirus (HPV) [1] infection is the most 
common sexually transmitted infection and can be 
passed on through genital contact or by skin-to-skin con-
tact [2, 3]. In the majority of cases, HPV infections are 
transient and cleared up within a few months after acqui-
sition. However in some cases, HPV infection can per-
sist and progress to cancer. The over 100 different HPV 
types identified have been divided into high and low risk 
types according to the risk for progression to cancer. 
High risk oncogenic HPV types (especially 16, 18, 31 and 
45) are known to be primarily responsible for cancerous 
and precancerous lesions of the ano-genital area in both 
males and females. Overall, virtually all of cervical can-
cers, 88% of anal cancers, 43% of vulvar cancers, 70% of 
invasive vaginal carcinomas and 50% of all penile cancers 
worldwide can be attributed to HPV. The proportion of 
head and neck cancers caused by HPV is lower but not 
negligible [4]. Cervical cancer is the second most com-
mon cancer in young women in the European Union, and 
nearly all cases are attributable to HPV infection, the pri-
mary cause being the persistent infection of the genital 
tract by high-risk types (HPV 16/18/33/45) [5–7]. The 
second category, low-risk HPV types, do not cause can-
cer but are the agents of skin and genital warts. Low-risk 
HPV types include types 6 and 11, that are responsible 
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for about 90% of all genital warts and can cause recurrent 
respiratory papillomatosis [8].
In Italy, a cervical cancer screening based on cytol-
ogy is recommended every 3  years for women aged 
from 25 to 64  years [9, 10]. In addition to cervical can-
cer screening, HPV vaccination is offered actively and 
free of charge to girls aged 12 since 2007. HPV vaccines 
are designed to prevent HPV infection and HPV-related 
diseases, as demonstrated in clinical trials. There are cur-
rently two commercially available vaccines in Europe: the 
quadrivalent vaccine  Gardasil® and the bivalent vaccine 
 Cervarix®. Both vaccines protect against high-risk HPV 
16 and 18. The quadrivalent vaccine also includes pro-
tection against HPV 6 and 11, which are responsible for 
most cases of genital warts. The two vaccines are indi-
cated for the protection of premalignant genital lesions 
(cervical, vulvar and vaginal) and cervical cancers; the 
indication of the quadrivalent vaccine also includes pre-
malignant anal lesions, anal cancers and genital warts.
In Italy, each region is allowed to include additional age 
cohorts target group in the HPV vaccination programme; 
between 2014 and 2015, nine regions (Veneto, Liguria, 
Friuli-Venezia Giulia, Apulia, Sicily, Sicilia, Calabria, 
Molise, Trentino and Sardinia) extended the active vac-
cination programme to 12 year old boys. The vaccination 
program was initially based on a three dose regimen, but 
was subsequently changed to a 2-dose schedule in 2014.
A nine-valent vaccine (Gardasil  9®), developed with the 
aim to protect against nine HPV types (6, 11, 16, 18, 31, 
33, 45, 52 and 58) was approved by the Food and Drug 
Administration in December 2014, and by the Euro-
pean Medicines Agency in June 2015 [11, 12]. Data con-
firm that types 16, 18, 31, 33, 45, 52 and 58 are amongst 
those most frequently detected [13]. Therefore, the nine-
valent vaccine is expected to provide coverage against 
the majority of high-risk HPV types with carcinogenic 
properties [11]. With the addition of five HPV types com-
pared to its predecessor, the nine-valent vaccine has the 
potential to prevent 70–90% of cervical, vulvar, vaginal 
and anal cancers, and 45–80% of precancerous cervical 
lesions [13, 14].
The total direct costs associated with the annual inci-
dent cases of HPV-related diseases [cervical cancers, pre-
cancerous cervical lesions, vaginal cancer, vulvar cancer, 
penile cancer, anal cancer, head and neck cancer, genital 
warts and recurrent respiratory papillomatosis (RRP)] 
including the cost of the diagnosis were estimated to 
be €529 million in 2011 in Italy [15]. The World Health 
Organization and the supervisory authority for public 
contracts in Italy, recommend that the decision-making 
process be based on both the quality of goods and ser-
vices, as well as the best achievable price.
Several mathematical models have estimated the 
potential population impact of HPV vaccination  on the 
burden of cervical cancer [16–22]. In Italy, like in other 
countries in Europe, there are numerous published stud-
ies assessing the cost-effectiveness of HPV vaccines [9, 
19, 23–28]. Such studies conclude that the vaccination 
of girls with the bivalent and/or quadrivalent vaccines is 
cost-effective. More recently, the BEST II study estimated 
that universal vaccination (i.e. girls and boys vaccination) 
was also cost-effective in the Italian context [22]. On the 
other hand, the cost-effectiveness of 9-valent HPV vacci-
nation was assessed in the United States. Three models 
were presented during the advisory committee on immu-
nization practices (ACIP) meeting on February 26th 2015 
[29–31]. Results of those studies showed that a universal 
vaccination programme with the nine-valent vaccine was 
likely to be cost-effective and even cost-saving compared 
to the current universal vaccination programme with 
the quadrivalent vaccine in the US, if a premium price of 
+10% was considered. Similar conclusions were drawn in 
Canada [32]. Brisson et al. [33] found that if the premium 
price of the nonavalent vaccine is below $13 per dose, the 
nine-valent vaccine would be cost saving with respect to 
the quadrivalent vaccine in the US setting. Robust cost-
saving results were also found by Chesson et al. [34]. In 
Europe, the most recent study from Boiron et  al. [35] 
showed that vaccinating 60% of girls and 40% of boys 
aged 9 in Austria with a nine-valent vaccine would sub-
stantially reduce the incidence of cervical cancer and be 
cost effective compared to the current strategy.
The objective of this study was to provide realistic esti-
mates of the epidemiological and economic impact of the 
implementation of the 9-valent HPV vaccine program 
for both girls and boys in Italy compared to the current 
clinical practice using a 4-valent (HPV 6/11/16/18) or 
bivalent (HPV 16/18) vaccine for girls only, in a short 
and long-term horizon from the national health service 
perspective.
Methods
Mathematical model
A previously published US model, simulating the natural 
history of HPV-infections and estimating the cost asso-
ciated with HPV-related diseases, has been extended to 
account for infections and diseases attributable to HPV 
genotypes 31, 33, 45, 52, 58 and adapted to Italy in order 
to estimate the cost-effectiveness of the nine-valent vac-
cine [19, 20].
The model is a deterministic, dynamic, ODE-based sus-
ceptible-infected-recovered-susceptible (SIRS) transmis-
sion model. This open-population based model consists 
of:
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  • A demographic model describing birth, ageing, and 
death.
  • A behavioural model describing sexual mixing pat-
terns.
  • HPV infection and disease models describing trans-
mission and disease occurrence.
Whereas HPV 6, 11, 16 and 18 are modelled separately, 
the five additional types are combined into a single set 
of compartments. All together, the model accounts for 
the transmission dynamics of nine HPV types: 16, 18, 6, 
11, 31, 33, 45, 52, and 58, and simulate the occurrence of 
genital warts; RRP; precancers such as cervical intraepi-
thelial neoplasia (CIN); cervical, vulvar, vaginal, penile, 
anal, and head/neck cancers related to these HPV types.
The current analysis follows a conservative approach 
and considers an additional clinical benefit of the nine-
valent vaccine only for CIN, cervical and anal cancers. 
The status quo was assumed for other diseases.
In addition, as RRP, penile and head and neck cancers 
are not included in the vaccine label, those indications 
were not incorporated in the base case analysis, but they 
were considered in the sensitivity analyses.
Two different strategies with the nine-valent vaccine 
(cervical cancer screening and the nine-valent vaccine for 
girls only or both boys and girls) were compared to four 
alternative strategies:
  • Cervical cancer screening and the quadrivalent vac-
cine for girls only;
  • Cervical cancer screening and the quadrivalent vac-
cine for both boys and girls;
  • Cervical cancer screening and bivalent vaccine for 
girls only;
  • Screening strategy only.
Epidemiological model parameters
The numerous model inputs of the epidemiological 
model are divided into demographics, sexual behavior, 
disease and treatment patterns, screening, and natural 
history of disease. The parameter estimates were derived 
from published data and a calibration process. Further 
details on the calibration material and techniques are 
presented in the section “Model calibration and valida-
tion”. The main set of epidemiological data are displayed 
in Additional file 1. All remaining model parameters and 
their values have been previously reported in detail in a 
technical report from Elbasha et al. [19].
Demographics
The model population reflects the current size and demo-
graphic characteristics (gender distribution and all-cause 
mortality rates) of the Italian population. These estimates 
were retrieved from the Italian National Institute of Sta-
tistics [10].
Sexual behaviour
Each age group consists of persons with low, medium 
or high sexual activity. Data on sexual behaviour in Italy 
were scarce or differed in several aspects from the inputs 
needed to inform the model. The results from the United 
Kingdom (UK) NATSAL-3 study were used. They were 
deemed to be applicable to the Italian setting according 
to experts’ opinion as well as being consistent with previ-
ously published economic literature (Haeussler et al.) [21, 
22, 36].
The degree of sexual mixing among members of differ-
ent age cohorts and sexual activity groups (0 represent-
ing no mixing, and 1 representing a maximal mixing) was 
set up in similar to the US model and adjusted during the 
calibration process [19].
Natural history of disease
The progression from infection to disease follows a 
similar natural history structure as the initial US model. 
Since transmission rates are not directly observable, cali-
bration techniques were used to obtain the best set of 
parameters.
Disease and treatment patterns
Women with precancerous lesions [CIN, vaginal intraepi-
thelial neoplasia (VaIN) and vulvar intraepithelial neopla-
sia (VIN)] or with cancer were classified into undetected, 
detected or treated categories. The proportion of women 
recognising their disease and seeking treatment and the 
proportion of treated women were estimated through the 
model calibration.
The women who had a benign hysterectomy and the 
ones who were treated and cured for cervical cancer were 
no longer at risk of cervical cancer. The incidence rates of 
hysterectomy by age were retrieved from the most recent 
Italian publication [9].
The annual probability of death for each HPV-related 
cancer, stratified by age and stage, were obtained by com-
bining the data from two sources: the age-specific data 
from EUROCARE-5 and the stage-specific data from the 
BEST II study [22, 37].
Screening
In Italy, a cervical cancer screening with cytology is rec-
ommended every 3  years for women aged from 25 to 
64  years [9, 10]. HPV testing as primary screening in 
women ≥30  years to be performed every 5  years has 
been introduced in a few regions, but data are still very 
scarce. Therefore, the focus of the analyses was Pap 
smear testing. The model reflected the current Italian 
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situation where 77% of women receive gynecological can-
cer screening tests at least once every 3 years, as reported 
by the Italian national screening observatory (Osservato-
rio nazionale screening). The model was also informed by 
the age specific screening coverage rates in the past year, 
using two different sources to cover all the age groups 
[22, 38]. No screening for women aged 0–10 and 75+ 
was assumed.
The proportion of women who received a follow-up 
visit after an abnormal PAP smear test (70.52%) was 
estimated from the English Cervical screening pro-
gramme 2013–2014, as no Italian source was found 
[39]. In terms of diagnostic performance, the sensitiv-
ity and specificity of the colposcopy were 90 and 48% 
respectively, whereas the specificity of the Pap test was 
95.7% [9].
Economic model parameters
The epidemiologic model adapted to the Italian popu-
lation was then connected to the economic model. The 
latter simulates the costs and utilities associated with the 
HPV-cases and related diseases and assesses the impact 
of each prevention strategy. The inputs for the economic 
model are divided into vaccination strategy, vaccine 
properties, costs, and health-related quality of life.
Vaccination strategy
The current vaccination program with the bivalent and 
quadrivalent HPV vaccine in Italy is for girls at their 12th 
year of age, with recent data showing a coverage rate of 
71.1% [40]. The vaccination consists of a two-dose sched-
ule with a high adherence rate (proportion receiving 
the 2nd dose after the 1st one) of 90% [41]. It has been 
assumed that a vaccination programme with the nine-
valent vaccine and or the addition of boys’ immuniza-
tion would have the same performance (coverage and 
adherence).
Vaccine properties
The prophylactic efficacy of the vaccine or vaccine 
degree of protection was based on clinical trial data 
(Table  1) [42–47]. The duration of protection against 
vaccine types (6/11/16/18/31/33/45/52/58) was assumed 
to be lifelong. This parameter was tested in sensitivity 
analyses adopting a conservative approach with a lower 
duration of 20 years [19, 20]. The model makes a distinc-
tion between the level of protection against the infec-
tion and again the disease resulting from a breakthrough 
infection and considers different efficacy values for each. 
It is further assumed that these “breakthrough” infec-
tions are transmissible. The efficacy on head and neck, 
penile and RRP diseases was assumed to be conferred 
through protection against infection only. As they are 
not included in the vaccine label, these indications were 
not incorporated in the base case analysis but consid-
ered in the sensitivity analyses.
A two-dose regimen was considered in the model for 
the quadrivalent vaccine and also for the nine-valent vac-
cine to reflect the on-going trial. We assumed that if only 
one dose was administrated, the vaccine would have no 
efficacy.
In recent World Health Organization (WHO) guide-
lines on cervical cancer it was highlighted that the dura-
tion and strength of effectiveness of cross-protection was 
still to be demonstrated. Therefore, no cross-protection 
was assumed in the base case [48].
Cost of vaccination
In Italy, the vaccination programme is financed at 
Regional level and therefore it can be largely different 
in terms of age and number of the target cohorts, 
catch-up programmes and access procedure. For this 
reason, the cost of each vaccine dose is subject to a 
wide variability across the regions and over time [22]. 
The maximum price for public healthcare providers 
was set at €104.00, which corresponds to the ex-factory 
price per dose negotiated by the Italian agency for 
medicines. The cost of the 9-valent vaccine was not 
available in Italy since the product is not yet marketed. 
A theoretical base case price for the nine-valent vac-
cine of €120.00 was chosen, the equivalent of the price 
set in the public sector in the US.1 The price of both 
vaccines was varied in the sensitivity analyses. Moreo-
ver threshold analyses were conducted to find the cost-
effective price for a ceiling ratio of 25,000–40,000€/
QALYs, which is in line with Italian guidelines [49]. The 
administration cost was set at €6.6 [22].
Cost per episode of care
The costs per episode of care of each HPV-related dis-
ease, defined as the cost of management from diagnosis 
to resolution of the case, were estimated from the BEST 
II study and Baio et al. and are displayed in Table 2 [15, 
22]. The productivity losses as a result of HPV disease 
were not included in the model.
Cost of screening and diagnostic tests
The Italian reimbursement tariffs from the Italian Minis-
try of Health were used to extract the costs of PAP test, 
colposcopy and biopsy [50].
All costs were updated to 2014 Euros using the 
National Price Index for the whole community [51].
1 As of July 6th 2015 http://www.cdc.gov/vaccines/programs/vfc/awar-
dees/vaccine-management/price-list/: USD = 0.906249 EUR.
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Health‑related quality of life
Age-specific utilities for the Italian general population 
were not available in the literature. In a report from the 
Istituto Superiore di Sanita’, utilities for the Italian gen-
eral population were assumed equal to the US popula-
tion, thus the same assumption was used in the model 
[52]. Disease-related utilities were collected from the 
BEST II study [22] for all the diseases except for recur-
rent respiratory papillomatosis which was collected from 
Lindman et  al. [53]. and are summarized in Table  2. 
Health utility values from the BEST II study were based 
on an Italian Time Trade-off study on HPV-related dis-
eases [54]. We assumed that the quality of life for can-
cer survivors after successful treatment was the same as 
healthy women of the same age. The alternative set of 
utilities that were used for the sensitivity analysis is from 
Elbasha et al. [19, 20].
Discounting
Both costs and outcomes were discounted to present 
value at a rate of 3% per the Italian pharmacoeconomic 
guidelines [49]. Alternative discount rates of 1.5% for 
outcomes, 0 and 6% for both costs and outcomes were 
used in the sensitivity analysis.
Model calibration and validation
Despite a good level of accuracy in the choice of the 
inputs, epidemiological results may not be consistent 
with observed Italian data reported in the national 
statistics. For this reason it was necessary to perform 
a calibration, the process in which epidemiologi-
cal model inputs are tuned in order to obtain results 
closer to real data. The targets of the calibration are 
data on incidence and mortality rates of HPV-related 
diseases.
Table 1 Summary table on vaccine assumptions Giuliano et al. [44] for males and Elbasha and Dasbach [19] for females
* Preventing male genital infections through male vaccination is assumed to prevent transmission of genital infections to females
** Preventing female genital infections through vaccination is assumed to prevent transmission of genital infections to males
Vaccine assumptions (proportion of exposed people avoiding the infection) HPV 16 HPV 18 HPV 31, 33, 
45, 52 and 58
Cervical cancer
Vaccine efficacy for preventing cervical HPV16/18/31/33/45/52/58 infections
 Male* 0.411 0.621 0.411
 Female** 0.76 0.963 0.76
Degree of protection of the vaccine against cervical HPV16/18 infections becoming persistent 0.988 0.984 0.988
Degree of protection of the vaccine against HPV16/18 -related CIN 0.979 1 0.979
Vaginal and vulvar cancers
Vaccine efficacy for preventing vaginal/vulvar HPV16/18 infections
 Male* 0.411 0.621
 Female** 0.76 0.963
Degree of protection of the vaccine against vaginal/vulvar HPV16/18 infections becoming persistent 0.988 0.984
Degree of protection of the vaccine against HPV16/18-related/VaIN/VIN 1 1
Anal cancers
Vaccine efficacy for preventing anal HPV16/18 infections
 Male* 0.411 0.621 0.621
 Female** 0.76 0.963 0.963
Degree of protection of the vaccine against anal HPV16/18 infections becoming persistent
 Male* 0.787 0.96 0.96
 Female** 0.988 0.984 0.984
Degree of protection of the vaccine against HPV16/18 -related AIN 0 0 0
Penile and H&N cancers
Vaccine efficacy for preventing anal/penile**/H&N HPV16/18 infections
 Male* 0.411 0.621
 Female** 0.76 0.963
Degree of protection of the vaccine against anal/penile/H&N HPV16/18 infections becoming persistent
 Male* 0.787 0.96
 Female** 0.988 0.984
Degree of protection of the vaccine against HPV16/18 -related AIN/PIN/H&N neoplasia 0 0
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Overall and age-specific incidence data for cervical, 
anal, vaginal, vulvar and penile cancers were found in 
the report from the Institut Catala’ d’Oncologia (ICO)—
Information center on HPV. The aim of this report was to 
compile and centralize updated data and statistics from 
the official Italian registry on HPV and related cancers; 
age specific values were extracted from the graphs [55]. 
The ITACAN database was used for incidence data on 
cancers in oral cavity, oropharynx and larynx. Overall 
incidence of genital warts was found in an Italian study 
(Baio et al.). This Italian study provided also overall inci-
dence for CIN 1 and CIN 2–3 incidence. Nevertheless, 
the reported values were much lower than other available 
data (Hartwig). Therefore, UK data were also considered 
as a higher bound of plausible data.
Since the model studies HPV-induced diseases only, 
target epidemiological values were calculated by multi-
plying the incidence or the mortality with the percentage 
of the disease that can be attributed to HPV infection.
The proportion of diseases attributable to HPV infec-
tion (for the 2-valent, 4-valent or 9-valent vaccines) were 
found in the literature [13, 56]. The model was calibrated 
to attribute 73% of CIN 2/3 and cervical cancer inci-
dence to HPV 16 and 18 and 17% to HPV 31, 33, 45, 52, 
and 58.
HPV-related head and neck cancers were calculated by 
weighting HPV-related oral cancers, oropharynx cancers 
and larynx cancers on their overall incidence.
The calibration process involved many rounds of itera-
tions to move model outcomes closer to the targets. The 
following model outcomes were compared against the 
calibration target in each iteration: cervical cancer inci-
dence, genital warts incidence, vaginal/vulvar/penile/
anal/head and neck cancer incidence, and mortality rates 
of cervical/vaginal/vulvar/head and neck cancer.
The variables that affect all or most of the outputs are 
referred to as global variables. These include behavioural 
parameters, natural history of disease, transmission 
rates and all-cause mortality. They were first adjusted 
by changing transmission rates. The variables that affect 
only specific outputs are referred to as specific variables. 
These include disease-specific probability of death and 
Table 2 Summary table on costs and utilities for HPV-related disease
HPV-related disease Cost (€) References Utility References
Females Males Males Females
CIN 1 452.0 [22] 0.8396 [22]
CIN 2 1485.0 [22] 0.7967 [22]
CIN 3, CIS 1971.8 [22] 0.8396 [22] (assumption on CIS)
Cervical cancer, local disease 20,652.7 [22] 0.54375 [22]
Cervical cancer, regional disease 35,930.4 [22] 0.5701 [22]
Cervical cancer, distant disease 34,574.7 [22] 0.4517 [22]
VaIN 2 3237.0 [22] 0.9793 [22]
VaIN 3, CIS 3237.0 [22] 0.9793 [22]
Vaginal cancer, local disease 7703.2 [22] 0.54375 [22]
Vaginal cancer, regional disease 19,835.9 [22] 0.5701 [22]
Vaginal cancer, distant disease 29,646.9 [22] 0.4517 [22]
Vulvar cancer, local disease 7183.7 [22] 0.54375 [22]
Vulvar cancer, regional disease 16,032.6 [22] 0.5701 [22]
Vulvar cancer, distant disease 20,365.4 [22] 0.4517 [22]
Penile cancer, local disease 10,497.6 [15] 0.7922 [22]
Penile cancer, regional disease 10,497.6 [15] 0.7922 [22]
Penile cancer, distant disease 10,497.6 [15] 0.7922 [22]
Anal cancer, local disease 9812.4 9812.4 [22] 0.653 0.69615 [22]
Anal cancer, regional disease 18,480.4 18,480.4 [22] 0.4175 0.5172 [22]
Anal cancer, distant disease 11,993.6 11,993.6 [22] 0.1998 0.2244 [22]
Head & Neck cancer, local disease 10,081.7 10,081.7 [22] 0.8171 0.7413 [22]
Head & Neck cancer, regional disease 28,572.1 28,572.1 [22] 0.5601 0.551 [22]
Head & Neck cancer, distant disease 28,572.1 28,572.1 [22] 0.5601 0.551 [22]
Genital warts 700.3 495.8 [15] 0.6961 0.7761 [22]
Recurrent respiratory papillomatosis 195,814.9 195,814.9 [15] 0.795698925 0.795698925 [53]
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rate of seeking treatment, and were used to fine-tune 
each disease area.
Model analyses
The model was used to estimate the total number of 
disease events associated with HPV vaccine types 
(6/11/16/18/31/33/45/52/58-related); the incidence 
and mortality (cervical cancer, CIN, anal cancer and 
genital warts); the costs of vaccination, screening, 
diagnosis and management of the disease; the quality-
adjusted life years (QALYs) of the model population. 
Results were reported over 100  years for the different 
strategies tested. Incremental cost-effectiveness ratios 
(ICERs) were then calculated by dividing the difference 
in the average accumulated costs by the average QALYs 
gained.
Sensitivity analyses were performed deterministically, 
modifying the value of one base case parameter at a time. 
The following key parameters were tested: vaccine price 
(with a low price of 56€ for the quadrivalent vaccine and 
Cervarix, and 80€ for the nine-valent vaccine), dura-
tion of protection (20 years), utilities from Elbasha et al. 
discount rates (1.5% instead of 3% for outcomes), and 
the inclusion of RRP, penile and head and neck cancer 
indications.
Results
Calibration
Most of the overall rates are very close to published data 
(less than 15% difference). Target were not matched 
closely for overall vaginal and vulvar cancer incidence 
and mortality. Age-specific values are generally difficult 
to calibrate, given the numerous parameters at stake and 
the diversity of the sources. Overall the calibrated age 
specific values were close to the observed data with the 
exception of the older age groups (75+).
Epidemiological results
The nine-valent vaccine girls-only vaccination and the 
quadrivalent vaccine girls-only vaccination are associ-
ated with a 76 and 63% decrease in incidence of cervical 
cancer respectively, over 100  years, as shown in Fig.  1. 
Overall, the estimated number of cervical disease events 
prevented with the nine-valent vaccine in 100  years in 
comparison with the quadrivalent vaccine was 16,678 for 
cervical cancer, 82,598 for CIN1, and 127,742 for CIN2+, 
as shown in Table 3. In total, the reduction in the num-
ber of cases of precancerous lesions (CIN 1, CIN 2/3) 
and genital warts occurred within 5th years of the start of 
the vaccination programme. The reduction in incidence 
of HPV-related cancers and deaths from HPV-related 
Fig. 1 Epidemiological impact of three vaccination strategies on the incidence and mortality of cervical diseases (related to related to HPV 
16/18/31/33/45/52/58)
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cancers was more gradual, reflecting the fact that HPV-
related cancers are diseases with slower progression.
Switching from a girl-only vaccination with the quadriva-
lent vaccine to a universal vaccination with the nine-valent 
vaccine showed significant health benefits. With respect to 
the quadrivalent vaccine, additional 22,640 prevented cases 
of cervical cancer, 105,431 of CIN1, and 170,286 of CIN2+ 
were associated with the universal vaccination. Furthermore, 
the comparison between the nine-valent vaccine universal 
vaccination and the quadrivalent vaccine girls-only vaccina-
tion (Table  3) estimated that vaccinating boys will prevent 
1508,505 cases of genital warts among males, 358,140 cases 
of genital warts among females, and 8111 cases of anal can-
cer. This corresponds to an additional decrease in incidence 
with respect to the nine-valent vaccine girl-only vaccination 
of 4% in cervical cancer, 4% in CIN1, 4% in CIN2+ (Fig. 1), 
and 7% in genital warts among female (Fig. 2).
Cost-effectiveness results
The ICER of the nine-valent vaccine with respect to the 
quadrivalent vaccine was 4483€/QALY when considering 
girls-only vaccination and 10,463€/QALY for a universal 
Table 3 Disease events prevented with  the nine-valent 
vaccine universal vaccination in comparison with the cur-
rent strategy (the quadrivalent vaccine girls-only vaccina-
tion)
Disease event Years since start of vaccination 
programme
5 25 50 100
Females
 Cervical cancer 0 367 4623 22,640
 CIN 1 23 6961 34,753 105,431
 CIN 2/3 25 10,193 54,709 170,286
 Vaginal cancer 0 0 13 88
 VAIN 2/3 0 0 0 0
 Vulvar cancer 0 1 21 130
 Genital warts and HPV 
6/11-related CIN 1
33 2438 6270 13,658
 Genital warts 1411 61,285 161,443 358,140
 Anal cancer 0 11 318 2619
Males
 Genital warts 6101 208,935 615,645 1508,705
 Anal cancer 0 28 748 5492
Fig. 2 Epidemiological impact of three vaccination strategies on the incidence of genital warts and anal cancer (related to related to HPV 
16/18/31/33/45/52/58)
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vaccination (Table  4). The implementation of the nine-
valent vaccine universal vaccination in comparison to a 
girls-only program with the quadrivalent vaccine was 
associated with a cost per QALY gained of 13,541€. In 
the instance where the vaccination covered only girls, the 
nine-valent vaccine was cost-saving with respect to the 
bivalent vaccine.
The comparison of the nine-valent vaccine with the 
screening only strategy scored an ICER of 2592€/QALY for 
the girls only vaccination and 5855€/QALY in the case of a 
universal vaccination is selected. As shown in Fig. 3 switch-
ing from the quadrivalent vaccine to the nine-valent vaccine 
girls-only vaccination is cost-effective up to a price of €201 
per dose, considering a threshold for the ICER of 40,000€/
QALY. All the threshold prices can be found in Fig. 3.
Sensitivity analyses
One-way sensitivity and scenario analyses were con-
ducted and the cost-effectiveness results are displayed 
in Tornado diagrams in Fig.  4. The bivalent vaccine 
remained dominated by the nine-valent vaccine in all 
sensitivity analyses. The low price alternative decreased 
the ICER with respect to base case in the nine-valent vac-
cine universal vs the quadrivalent vaccine girls. In the 
other comparisons, considering that only the vaccine will 
change but not the target population, the ICER increased 
instead, but remained well beyond the minimum thresh-
old of 25,000€/QALY. The ICERs were very sensitive to 
the discount rate. A higher discount rate of 6% substan-
tially reduced both costs and outcomes and resulted in 
significantly higher ICERs for the three comparisons: 
19,400€/QALY for the comparison between the nine-
valent vaccine and the quadrivalent vaccine in a girls-only 
vaccination strategy, 39,182€/QALY for the nine-valent 
vaccine and the quadrivalent vaccine in a universal vac-
cination and 27,841€/QALY for the nine-valent vaccine 
universal strategy versus the quadrivalent vaccine girls-
only strategy. Testing no discount rate greatly increased 
costs and outcomes and produced the lowest ICERs for 
the comparison between the nine-valent vaccine and the 
quadrivalent vaccine in a girls-only vaccination strategy 
(556€/QALY) and for the nine-valent vaccine and the 
quadrivalent vaccine in a universal vaccination (2760€/
QALY). For the nine-valent vaccine universal strategy 
Table 4 Cost effectiveness results of the base case analysis
Comparison New technology Comparator Incremental 
costs
Incremental 
QALYs
Cost per QALY 
gained
New tech Comparator Costs QALYs Costs QALYs
HPV9 girls HPV4 girls €183.29 27.53857 €180.60 27.53797 2.69 0.0006 €4483
HPV9 girls HPV2 girls €183.29 27.53857 €188.92 27.53571 −5.63 0.00286 Cost saving
HPV9 universal HPV4 universal €213.64 27.54041 €206.63 27.53974 7.01 0.00067 €10,463
HPV9 universal HPV4 girls €213.64 27.54041 €180.60 27.53797 33.04 0.00244 €13,541
Fig. 3 Price threshold analysis
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versus the quadrivalent vaccine girls-only strategy, the 
lowest ICER (5807€/QALY) was achieved while test-
ing a lower discount rate of 1.5% only for outcomes and 
of 3% for costs. A 1.5% discount rate for outcomes-only 
also decreased significantly the ICER for the compari-
son between the nine-valent vaccine and the quadriva-
lent vaccine in a girls-only vaccination strategy (1546€/
QALY) and the nine-valent vaccine and the quadriva-
lent vaccine in a universal vaccination (3689€/QALY). A 
decrease in the duration of protection from lifelong in 
the base case to 20 years resulted in higher incremental 
costs and lower incremental QALYs producing an over-
all ICER increase (9 139€/QALY for the comparison 
between the nine-valent vaccine and the quadrivalent 
vaccine in a girls-only vaccination strategy, 18 167€/
QALY the comparison between nine-valent vaccine and 
the quadrivalent vaccine in a universal vaccination and 
20 845€/QALY when comparing a universal vaccination 
with the nine-valent vaccine and a girls-only vaccination 
with the quadrivalent vaccine). The ICERs were not very 
sensitive to the lower coverage rates in girls-only; when 
considering the male vaccination in both strategies, a 
lower overall coverage rate of 60% decreased the ICER to 
7165€/QALY. The change in utility values increased the 
ICER in the comparison with different target population, 
and remained close to the base case in the other two. 
Fig. 4 Tornado diagrams comparing the ICERs resulting from the sensitivity analysis
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Similarly, the inclusion of RRP, penile and H&N cancers 
indication left the ICER almost unchanged from the base 
case in the comparisons with the same target population, 
but it decreased the ICER to 7165€/QALY when compar-
ing a universal vaccination with the nine-valent vaccine 
and a girls-only vaccination with the quadrivalent vac-
cine. A lower adherence rate in males (85%) resulted in 
an ICER almost unchanged in both comparisons consid-
ering universal vaccination.
Discussion
In the current study, we assessed the cost-effectiveness of 
alternative vaccination strategies against HPV infection 
in the Italian setting comparing traditional bivalent and 
quadrivalent vaccines with the newly-available 9-valent 
vaccine.
The results show that the new nine-valent vaccine has 
a positive impact on cervical cancer and pre-cancerous 
lesions. This is of importance as the economic burden of 
cervical cancer in Italy is estimated at €147million [15]. 
The introduction of the new vaccination strategy with 
the nine-valent vaccine would reduce cervical cancer and 
CIN incidence by 77% in 100 years when vaccinating girls 
only, which is 13, 17 and 14% more for cervical cancer, 
CIN1 and CIN2+ respectively than with the quadriva-
lent vaccine girls-only vaccination strategy. Considering a 
girls-only vaccination, the analyses provide evidence that 
the nine-valent vaccine is highly cost-effective in com-
parison to the quadrivalent vaccine (ICER 4483€/QALY) 
and cost-saving compared to HPV2. This is a novel result 
in the Italian setting, as previous comparisons did not 
include the nine-valent vaccine [9, 22].
The results also suggest that universal vaccination with 
the nine-valent vaccine could be a cost-effective if com-
pared to girls-only vaccination with the quadrivalent vac-
cine. The benefits of introducing male vaccination have 
previously been demonstrated with the quadrivalent vac-
cine in Italy with the BEST II study [19, 22]. A universal 
vaccination strategy with the nine-valent vaccine was still 
cost-effective against the quadrivalent vaccine universal 
(ICER 10,463€/QALY) and the quadrivalent vaccine girls-
only (ICER 13,541€/QALY). Sensitivity analyses showed 
that results were mostly robust. The ICER was very sen-
sitive to discount rates and the duration of protection. 
Using a higher discount rate or a reduced duration of 
protection significantly increased the ICER while no dis-
count or a 1.5% discount rate only for outcomes substan-
tially decreased the ICER. A lower coverage rate in both 
boys and girls or a lower adherence in males resulted in 
an ICER almost unchanged. This sensitivity to discount 
rates was expected since benefits of HPV vaccination 
occur several years after vaccination. The assumption of 
lifetime vaccine efficacy used in the base case was based 
on immunogenicity results and long-term protection of 
the vaccine available for the quadrivalent vaccine as well 
as models of long-term immune response [57, 58]. Thus, 
it is expected that the duration of protection against HPV 
genotypes 6/11/16/18/31/33/45/52/58 will be the same as 
the one for the quadrivalent vaccine since the two vac-
cines have structural similarities.
Showing potential cost-saving results is rarely seen for 
a new intervention, but our conclusion is in line with 
results obtained in the US and in Canada. In the US, 
three studies presented during the ACIP meeting showed 
that a universal vaccination programme with the nine-
valent vaccine was likely to be cost effective and even cost 
saving compared to the current universal vaccination 
programme with the quadrivalent vaccine [29–31]. Bris-
son et  al. and Chesson et  al. found the nine-valent vac-
cine cost saving with respect to the quadrivalent vaccine 
if the price premium is below $13 per dose [33, 34]. In 
Canada, Drolet et al. showed the cost-effectiveness of the 
nine-valent vaccine if compared to the quadrivalent vac-
cine with a price premium of $11 [32].
Since in Italy vaccination coverage rates of girls are 
lower than expected, passing to universal vaccination 
in Italian regions where only girls are vaccinated with 
the bivalent or quadrivalent vaccine would have sev-
eral benefits. First, it would protect females and males 
against HPV-related diseases and significantly reduce 
the remaining burden in both genders. Immunization of 
boys would indirectly protect girls from cancer and also 
be directly effective in the prevention of HPV-related 
diseases in men such as anal cancer [59, 60]. Moreover 
adding HPV vaccination of boys would decrease gender 
inequalities by protecting men exposed to male partners 
or unvaccinated females. Finally, it would allow HPV vac-
cination to become a standard vaccination in pre-adoles-
cents [59].
Moreover, in the study only precancerous cervical 
lesions and cervical cancers were considered. Therefore, 
the impact on genital warts and anal cancers were not 
taken into account which nevertheless represents a sub-
stantial burden of HPV-related diseases. Indeed, in Italy, 
an economic study reported that the costs associated 
with genital warts in men and women corresponded to 
almost one quarter of the total costs associated with HPV 
6, 11, 16, 18 [15, 59].
It is important to mention that our results may under-
estimate the additional benefits of the nine-valent vac-
cine vaccination on CIN. In the study from Hartwig 
et  al. results showed that the HPV6/11/16/18 are 
responsible for about 24% of CIN1, 45% of CIN2+, 
51% of vaginal cancer and 14% of vulvar cancer whereas 
HPV6/11/16/18/31/33/45/52/58 targeted by the nine-
valent vaccine account for 48, 82, 61 and 16% of CIN1, 
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CIN2+, vaginal cancer and vulvar cancer respectively [13]. 
It means that the 9-valent HPV infections were respon-
sible for twice as much of CIN1 and 1.8 times more for 
CIN2+ compared the 4-valent HPV whereas the results 
obtained from the calibrated model indicated that 9-valent 
HPV accounts for 1.3 times more for CIN1 and 1.2 times 
more for CIN2+ than 4-valent HPV, minimizing greatly 
the benefit of the nine-valent vaccine on CIN compared to 
the quadrivalent vaccine. Moreover, the 9-valent HPV vac-
cine with the five additional HPV types is likely to protect 
more against vaginal and vulvar cancers compared to the 
quadrivalent vaccine and HPV2 [13]. Therefore, the nine-
valent vaccine benefits on CIN, vaginal and vulvar cancers 
are probably underestimated in the present analysis.
Second, the model did not consider neonatal mor-
bidity and mortality due to cervical lesions. Indeed, 
women treated for CIN with excisional treatments are at 
increased risk of preterm delivery and low birth weight 
[61, 62]. By decreasing the number of women treated for 
CIN, the nine-valent vaccine vaccination could reduce 
preterm birth number and decrease neonatal morbidity 
and mortality. Finally, the indirect costs related to pro-
ductivity losses were not considered in this study. How-
ever HPV-related cancers affect women and men at work 
and their productivity. A study from Lerner et al. (2010) 
assessed the work performance and productivity impact 
of HPV in the US, and results showed that employed 
women with HPV-related cervical lesions had signifi-
cantly more at-work limitations, higher absence rates 
and significantly more productivity losses because of 
absences compared with healthy controls [63].
The duration of protection of the nine-valent vaccine, 
as well as the quadrivalent vaccine, is not known. In the 
base case scenario, a lifelong protection was assumed, 
in accordance with the literature [22]. In order to check 
the robustness of the results, in the sensitivity analysis 
the duration of protection was set as short as 20  years. 
Results showed that the duration of protection had a 
great impact on the cost-effectiveness. However the 
ICERs remained below the range of €25,000–€40,000 per 
QALY [considered as cost-effective in Italy by the AIES 
(Italian Association of Health Economics)] for all scenar-
ios except for the nine-valent vaccine universal versus the 
quadrivalent vaccine universal for a 10-year protection 
duration, indicating that vaccination of boys and girls 
aged 12 years remained a cost-effective strategy [49].
The major strength of this analysis is that the adaptation 
of this model originally designed for the US, was achieved 
through collection and selection of the appropriate data 
to reflect the Italian current epidemiological, medical and 
economical context. After the calibration process, the 
model was able to reproduce closely the observed inci-
dence and mortality of HPV-related diseases in Italy.
This study has some limitations. One limitation of this 
analysis is that the model involved numerous parameters 
and not all relevant parameters could be found from Ital-
ian-specific studies, which may limit the validity of the 
results. However, non-Italian specific values have been 
validated by experts and usually refer to population-inde-
pendent parameters. In order to simplify the calculations 
in the model, identical attribution to each of the five addi-
tional 9vHPV types, 31, 33, 45, 52, 58 was included. Finally, 
probabilistic sensitivity analysis was not performed because 
the interface of the model does not allow to quickly modify 
and evaluate several scenarios. However, the deterministic 
sensitivity analyses conducted to address the uncertainty 
showed that the conclusions of our analysis are robust.
Regarding screening practices, the pap smear test was 
used in the model and may not well represent the screen-
ing programme in Italy as this type of screening is being 
replaced by HPV-DNA testing in the country, and it 
could affect the cost effectiveness results. HPV-DNA test 
was not included in the analysis because Italian-specific 
data on the implementation of the HPV-DNA test are 
scarce, and the model does not allow for a flexibility in 
the use of mixed screening strategies.
Conclusion
This analysis showed the additional benefits of the new 
technology for the Italian population. With a vaccination 
coverage rate of about 70% with the nine-valent vaccine, 
future population will be less exposed to high-risk HPV 
type and thus the burden of HPV-related diseases in Italy 
could consequently be reduced. The vaccination of girls 
only and universal vaccination with the nine-valent vaccine 
are cost-effective strategies compared with the vaccination 
of girls with the bivalent or the quadrivalent vaccine.
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